Tc99m-sestaMIBI uptake in nonsecretory multiple myeloma

Hematology

Volumn 10, Issue 4, 2005, Pages 335-338

  Catalano, Lucio ^a   Andretta, Claudia ^a   Pace, Leonardo ^a   Del Vecchio, Silvana ^a   Salvatore, Barbara ^a   De Rosa, Gennaro ^a   Buonanno, Maria Teresa ^a   Paone, Gaetano ^a   Rotoli, Bruno ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Conventional imaging (CI); Monoclonal component (MC); Nonsecretory multiple myeloma; Tc99m sestaMIBI scintigraphy

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADULT; AGED; ARTICLE; BONE MARROW; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RADIODIAGNOSIS; REMISSION; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; X RAY;

AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MULTIPLE MYELOMA; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI;

EID: 29144439758     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330500067157     Document Type: Article

References (16)

1. Tirovola EB, Biassoni L, Britton KE, et al. The use of Tc-99m MIBI scanning in multiple myeloma. Br J Cancer 1996;74:1815-1820.
2. Adams BK, Fataar A, Nizami MA. Technetium-99m-sestaMIBI uptake in myeloma. J Nucl Med 1996;37:1001-1002.
3. Pace L, Catalano L, Pinto AM, et al. Different patterns of technetium-99m-sestaMIBI in multiple myeloma. Eur J Nucl Med 1998;25:715-720.
4. Fonti R, Del Vecchio S, Zanetti A, et al. Bone marrow uptake of 99m Tc-MIBI in patients with multiple myeloma. Eur J Nucl Med 2001;28:214-220.
5. Catalano L, Pace L, Califano C, et al. Detection of focal myeloma lesions by technetium-99m-sestaMIBI scintigraphy. Haematologica 1999;84:119-124.
6. Balleari E, Villa G, Garre S, et al. Technetium-99m-sestamibi scintigraphy in multiple myeloma and related gammopathies: A useful tool for the identification and follow-up of myeloma bone disease. Haematologica 2001;86:78-84.
7. Svaldi M, Tappa C, Gebert U, et al. Technetium-99m-sestamibi scintigraphy: An alternative approach for diagnosis and follow up of active myeloma lesions after high-dose chemotherapy and autologous stem cell transplantation. Ann Hematol 2001;80:393-397.
8. Pace L, Catalano L, Del Vecchio S, et al. Predictive value of technetium-99m sestamibi in patients with multiple myeloma and potential role in the follow up. Eur J Nucl Med 2001;28:304-312.
9. Cavo M, Galieni P, Gobbi M, et al. Nonsecretory multiple myeloma: Presenting findings, clinical course and prognosis. Acta Haematol 1985;74:27-30.
10. Abdalla IA, Tabbara IA. Nonsecretory multiple myeloma. South Med J 2002;95:761-764.
11. Catalano L, Andretta C, Pace L, Del Vecchio S, Fonti R, Pollio G, Salvatore B, Esposito C, Salvatore M, Rotoli B. Follow up of solitary plasmacytoma by Tc99m-sestaMIBI scintigraphy. Haematologia 2004;7:329-334.
12. Woolfenden JM, Pitt MJ, Durie BGM, Moon TE. Comparison of bone scintigraphy and radiology in multiple myeloma. Radiology 1980;134:723-728.
13. 99mTc-MIBI uptake in breast cancer cell lines. Eur J Nucl Med Mol Imaging 2004;31:521-527.
14. Andretta C, Catalano L, Pace L, Fonti R, Annunziata G, Rotoli B. 99mTc-sestaMIBI scintigraphy in thalidomide-treated refractory or relapsed multiple myeloma patients. Leuk Lymphma 2003;44:1081-1082.
15. Durie BG, Waxman AD, D'Agnolo A, William CM. Whole body 18F-FDG PET identifies high risk myeloma. J Nucl Med 2002;43:1457-1463.
16. Mileshkin L, Blum R, Seymour JF, Patrikeos A, Hicks RJ, Prince HM. A comparison of fluorine-18-fluoro-deoxyglucose PET and technetium-99m-sestaMIBI in assessing patients with multiple myeloma. Eur J Hematol 2004;72:32-37.